SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (Nasdaq:HEPH) today provided an update on its progress in negotiations with the Department of Health and Human Services (HHS) on a potential BioShield procurement contract for NEUMUNE®, the Company’s lead drug candidate for Acute Radiation Syndrome (ARS). On January 31, 2007, Hollis-Eden received notice from HHS that the agency is still in the process of evaluating the Company’s revised proposal and that, in order to allow the government the time needed to complete its evaluation, HHS has revised its estimated planned contract award date to March 7, 2007.
